Advaxis Inc., a biotechnology company developing cancer immunotherapies, has announced that principal investigator Nicola Mason, BVet.Med, PhD, DACVIM, of the University of Pennsylvania School of Veterinary Medicine, will present updated data from the ongoing ADXS-cHER2 study in canine osteosarcoma at the 2014 American College of Veterinary Internal Medicine (ACVIM) Forum on June 5, 2014, in Nashville, Tennessee. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer.
In her presentation, "Clinical Evaluation of a HER2/neu-Targeting Vaccine to Prevent Metastatic Osteosarcoma," Mason will provide updated data from the ongoing study in pet dogs with osteosarcoma. "We are excited that Dr. Mason will be presenting these encouraging data from our canine trial at the ACVIM Forum, which focuses on the latest developments in animal health," said Daniel J. O'Connor, CEO of Advaxis. "Without question, her research has not only been groundbreaking in the treatment of canine osteosarcoma, but the results have also affirmed the potential of ADXS-cHER2 as a treatment for a host of human cancers, including bone cancer and breast cancer, where the HER2 oncogene is overexpressed. In particular, these data, along with the strong parallel between canine and pediatric bone cancer, were instrumental in our recent decision to pursue a clinical development program with ADXS-cHER2 in pediatric osteosarcoma."